Login to Your Account



All hail hyaluronidase? Bid in phase II shows promise

By Randy Osborne
Staff Writer

Thursday, January 5, 2017

Analysts split on what the positive, pooled-groups phase II data in pancreatic cancer might mean for Halozyme Therapeutics Inc.'s larger, ongoing phase III trial, but the company sounded upbeat in a conference call on the top-line results from HALO 202.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription